Expert insights. Personalized for you.
Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company. MORE
for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis. MORE
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB: MORE
Food and Drug Administration ( FDA ) announced its first-ever approval of a marijuana-derived pharmaceutical drug On June 25, 2018, the U.S. MORE
TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC. MORE
-With More than 1.9 Million Square Feet of Greenhouses, Clever Leaves is One of the Largest Cannabis Cultivation and Extraction Companies in the World- CORRECTION…by … Read More. Press Release US MORE
Life-threatening side effects from pharmaceuticals led one man to try cannabis. In this testimonial, he shares how cannabis helped him overcome refractory lockjaw and severe nerve pain MORE
CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release. MORE
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee. MORE
According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report. MORE
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News MORE
Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop., MORE
Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals MORE
Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. MORE
8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks. MORE
The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN MORE
Cannabis Science Decriminalization Legalization Medical Marijuana 411 Politics Prohibition Addiction Opioids PharmaceuticalAmerica is in the throes of a major crisis. Opioid addiction has taken over many parts of the country and is taking a number of lives daily. The opioid crisis is at its breaking point right now. More people are spending time in hospitals or losing their lives to opioid overdose than ever before. According to the National Institute on Read Article. MORE
As farmers widely grow hemp for a variety of purposes, the pharmaceutical industry is not able to control the supply of CBD oil. The Department of Defense the provided grant making this study possible, in collaboration with GW Pharmaceuticals. MORE
study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours. MORE
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences. MORE
ST PETERSBURG, FL and KINGSTON, JAMAICA / ACCESSWIRE / May 10, 2020 / Duane Boise CEO of MMJ’s International’s Holding shares success for shipping natural … Read More. Press Release US MORE
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Enquiries: GW Pharmaceuticals plc. MORE
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this? MORE
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. While GW Pharmaceuticals’ Epidiolex has received a Schedule V designation from the DEA, all other CBD formulations remain in Schedule I. . Sales of the pharmaceutical CBD product Epidiolex are expected to comprise less than a third of that projected total. MORE
MEDICAL CANNABIS PHARMACEUTICALSTwo Health and Wellness Powerhouses Collaborate to Help Those Suffering from Seizures Through an Innovative and Fast-Acting Intranasal Spray Solution. CHICAGO – July 11, 2019 / Canna Newswire / – Nature’s Grace and Wellness & JC Pharma, Inc. have reached a much- anticipated agreement that will make a groundbreaking, new seizure treatment available to the public. MORE
GW Pharmaceuticals has been creating unusual blends of clinical cannabis for over two decades. Blog Featured Health Marijuana News Science Technology abnormal cbd CBD Epidiolex ethanol gpr GW Pharmaceuticals synthetic cbdEpidiolex is an abnormal, proprietary cannabidiol tincture that was developed for epilepsy. This clinical concoction has been under some well-deserved criticism for several reasons, such as a liver damage warning. MORE
Medicinal cannabis was legalised in portugal in June 2018 by Parliament, however only one cannabis-based medication is legal in Portugal; Sativex, produced by British firm GW Pharmaceuticals. Featured Mark Taylor UK / EU Cannabis Compliance Blog aurora cannabis Aurora Portugal European Paraliament GW pharmaceuticals PLMJ portugal Portuguese Health Ministry sativexIf you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor. MORE
Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. MORE
Alternative Medicine cannabis education industry Logical Fallacies medical marijuana medicine News Pharmaceuticals Science-Based Medicine Skepticism about cbd dr. roman fake placebo skeptic skeptical skepticism thc truthIt's not easy gathering my wits and going public about this. I'm saying this and sticking my neck out as one individual opposing a multi-million(billion?) dollar industry.¹. The post The Truth About CBD appeared first on Nature's Way Medicine ®. MORE
CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co., MORE
There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News MORE
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). MORE
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). MORE
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. MORE
Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog MORE
To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co., MORE
Here’s the press release. The research will focus on the optimisation of breeding and cultivating processes and the extraction of material to assess their efficacy of medical cannabis on prostate, melanoma and other cancer cells. All intellectual property from the trials will be owned by MGC, which is funding the research. MORE
Cannabis Featured Medical Marijuana News autism CBD oil Epilepsy GW Pharmaceuticals Sanjay GuptaLeading marijuana researchers now believe a cannabis compound could treat autism symptoms. Continue reading Dr. Sanjay Gupta: Researchers Are Focused On Treating Autism With Marijuana at The Fresh Toast. MORE
Pharmaceutical Related Topics 
The Fresh Toast
MARCH 20, 2019
Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals
Cannabis Law Report
SEPTEMBER 24, 2019
Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 12, 2020
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News
Cannabis Law Report
JUNE 28, 2020
The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN
Cannabis Law Report
NOVEMBER 10, 2019
Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop.,
Cannabis Life Network
OCTOBER 8, 2019
8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.
|
Leaf Science
DECEMBER 28, 2018
study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours.
Canna Newswire
MAY 21, 2019
To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co.,
Cannabis Law Report
JULY 23, 2019
TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC.
Puff Puff Post
MARCH 10, 2020
SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Canna Newswire
MAY 30, 2019
CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co.,
|
|
Cannabis Life Network
AUGUST 22, 2020
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine).
Cannabis Law Report
JULY 12, 2019
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this?
Cannabis Law Report
JULY 21, 2019
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB:
Cannabis Law Report
JULY 19, 2019
FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry.
Cannabis Law Report
OCTOBER 26, 2019
The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences.
Cannabis Law Report
SEPTEMBER 14, 2019
According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report.
Cannabis Law Report
JUNE 24, 2020
Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog
Leafly
APRIL 6, 2020
Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly.
Cannabis Law Report
MAY 30, 2019
CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release.
Cannabis Law Report
NOVEMBER 5, 2019
Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company.
Cannabis Law Report
JULY 13, 2019
There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News
Cannabis Law Report
JUNE 4, 2020
-With More than 1.9 Million Square Feet of Greenhouses, Clever Leaves is One of the Largest Cannabis Cultivation and Extraction Companies in the World- CORRECTION…by … Read More. Press Release US
Cannabis Law Report
MAY 12, 2020
ST PETERSBURG, FL and KINGSTON, JAMAICA / ACCESSWIRE / May 10, 2020 / Duane Boise CEO of MMJ’s International’s Holding shares success for shipping natural … Read More. Press Release US
Cannabis Law Report
NOVEMBER 23, 2019
for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.
Cannabis Law Report
JUNE 5, 2019
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee.
Cannabis Law Report
MAY 29, 2019
Here’s the press release. The research will focus on the optimisation of breeding and cultivating processes and the extraction of material to assess their efficacy of medical cannabis on prostate, melanoma and other cancer cells. All intellectual property from the trials will be owned by MGC, which is funding the research.
Nature's Way Medicine
MARCH 3, 2018
Alternative Medicine cannabis education industry Logical Fallacies medical marijuana medicine News Pharmaceuticals Science-Based Medicine Skepticism about cbd dr. roman fake placebo skeptic skeptical skepticism thc truthIt's not easy gathering my wits and going public about this. I'm saying this and sticking my neck out as one individual opposing a multi-million(billion?) dollar industry.¹. The post The Truth About CBD appeared first on Nature's Way Medicine ®.
Puff Puff Post
JANUARY 13, 2020
As farmers widely grow hemp for a variety of purposes, the pharmaceutical industry is not able to control the supply of CBD oil. The Department of Defense the provided grant making this study possible, in collaboration with GW Pharmaceuticals.
Medical Marijuana 411
MARCH 18, 2019
Cannabis Science Decriminalization Legalization Medical Marijuana 411 Politics Prohibition Addiction Opioids PharmaceuticalAmerica is in the throes of a major crisis. Opioid addiction has taken over many parts of the country and is taking a number of lives daily. The opioid crisis is at its breaking point right now. More people are spending time in hospitals or losing their lives to opioid overdose than ever before. According to the National Institute on Read Article.
Canna Newswire
JULY 11, 2019
MEDICAL CANNABIS PHARMACEUTICALSTwo Health and Wellness Powerhouses Collaborate to Help Those Suffering from Seizures Through an Innovative and Fast-Acting Intranasal Spray Solution. CHICAGO – July 11, 2019 / Canna Newswire / – Nature’s Grace and Wellness & JC Pharma, Inc. have reached a much- anticipated agreement that will make a groundbreaking, new seizure treatment available to the public.
The Fresh Toast
OCTOBER 1, 2019
Cannabis Featured Medical Marijuana News autism CBD oil Epilepsy GW Pharmaceuticals Sanjay GuptaLeading marijuana researchers now believe a cannabis compound could treat autism symptoms. Continue reading Dr. Sanjay Gupta: Researchers Are Focused On Treating Autism With Marijuana at The Fresh Toast.
Cannabis Law Report
FEBRUARY 26, 2019
Medicinal cannabis was legalised in portugal in June 2018 by Parliament, however only one cannabis-based medication is legal in Portugal; Sativex, produced by British firm GW Pharmaceuticals. Featured Mark Taylor UK / EU Cannabis Compliance Blog aurora cannabis Aurora Portugal European Paraliament GW pharmaceuticals PLMJ portugal Portuguese Health Ministry sativexIf you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.
Freedom Leaf
OCTOBER 15, 2018
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. While GW Pharmaceuticals’ Epidiolex has received a Schedule V designation from the DEA, all other CBD formulations remain in Schedule I. . Sales of the pharmaceutical CBD product Epidiolex are expected to comprise less than a third of that projected total.
Project CBD
DECEMBER 5, 2019
Life-threatening side effects from pharmaceuticals led one man to try cannabis. In this testimonial, he shares how cannabis helped him overcome refractory lockjaw and severe nerve pain
Project CBD
NOVEMBER 26, 2018
Food and Drug Administration ( FDA ) announced its first-ever approval of a marijuana-derived pharmaceutical drug On June 25, 2018, the U.S.
Cannabis Life Network
JULY 24, 2019
GW Pharmaceuticals has been creating unusual blends of clinical cannabis for over two decades. Blog Featured Health Marijuana News Science Technology abnormal cbd CBD Epidiolex ethanol gpr GW Pharmaceuticals synthetic cbdEpidiolex is an abnormal, proprietary cannabidiol tincture that was developed for epilepsy. This clinical concoction has been under some well-deserved criticism for several reasons, such as a liver damage warning.
43 
Let's personalize your content